非霍奇金淋巴瘤自体干细胞移植前基于放射免疫疗法的预处理方案。
Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma.
作者信息
Eskian Mahsa, Khorasanizadeh MirHojjat, Isidori Alessandro, Rezaei Nima
机构信息
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, 14194, Iran.
Network of Immunity in Infection, Malignancy & Autoimmunity (NIIMA), Universal Scientific Education & Research Network (USERN), Tehran, Iran.
出版信息
Int J Hematol Oncol. 2018 Jun 13;7(1):IJH01. doi: 10.2217/ijh-2017-0025. eCollection 2018 Mar.
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy and the sixth cause of death from cancer in the USA. Autologous stem cell transplantation (ASCT) is a potentially curative therapeutic option for many NHL patients. Choosing the most effective conditioning regimen prior to ASCT can lead to longer survival in these patients, and, as in many cases of high risk NHL, the only potentially curative option is stem cell transplantation. Radioimmunotherapy (RIT) is based on using radiolabeled monoclonal antibodies against tumoral antigens. Since lymphoma cells are sensitive to radiation, RIT has become a potential approach in treating NHL. In this review, we have discussed the efficacy and safety of RIT as an alternative conditioning regimen prior to ASCT.
非霍奇金淋巴瘤（NHL）是美国最常见的血液系统恶性肿瘤，也是癌症死亡的第六大原因。自体干细胞移植（ASCT）是许多NHL患者潜在的治愈性治疗选择。在ASCT之前选择最有效的预处理方案可使这些患者获得更长的生存期，而且在许多高危NHL病例中，唯一潜在的治愈选择就是干细胞移植。放射免疫疗法（RIT）基于使用针对肿瘤抗原的放射性标记单克隆抗体。由于淋巴瘤细胞对辐射敏感，RIT已成为治疗NHL的一种潜在方法。在本综述中，我们讨论了RIT作为ASCT之前替代预处理方案的疗效和安全性。
Zotero 插件